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from which only 32 were original research empirical studies (0.3 0/000). Most studies 
were cross-sectional (72%), with only (25%) being prospective. Patient reported out-
comes were the most frequent adherence measures (65%). The Big Five model was 
the most frequent personality explicative framework (71%), followed by self-efficacy 
and beliefs. Conscientiousness was identified as an important adherent personality 
predictor. Quality of studies ranged between 53% and 86% with an average value of 
67% (SD= 8.8%). ConClusions: Although adherence is a frequently studied topic, few 
studies consider personal traits as a forecasting factor of medication persistence. A 
new instrument considering Conscientiousness as behavior predictor is being devel-
oped, the CUMPLE-Q.
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objeCtives: Primary non-adherence (PNA) has been found to range from 1% 
to 57% with a mean and median of 16.4% and 15.0%, respectively. We abstracted 
patient-centered reasons for PNA and their prevalence from the peer-reviewed lit-
erature. Methods: A systematic review using PubMed was conducted. A backward 
search of each abstracted article was performed as well as a review of each abstracted 
article’s reference list. Patient-provided reasons for PNA were abstracted from each 
reviewed article Results: A total of 131 articles met search-term criteria, and 19 
contained patient-provided reasons for PNA. Eleven additional articles were identi-
fied from backward citation searches and/or review of the 19 article’s reference list 
for a total of 30 studies. Fifty unique reasons for PNA were abstracted. After qualita-
tive analysis, they were reduced to seven mutually-exclusive reasons. Prescription-
medication affordability was the most common reason for PNA (80% of studies), 
followed by lack of perceived need for the medication (67% of studies), perceived 
medication concerns (53% of studies), lack of perceived drug efficacy (33% of studies), 
forgetfulness (33% of studies), access barriers (33% of studies), and patient knowledge 
(27% of studies). ConClusions: PNA is common both. Few adherence interventions 
have been developed and evaluated for PNA. The first step in developing adherence 
interventions for PNA is to gain an understanding of patient-centered reasons for 
PNA. This review identified the seven foremost reasons for PNA from 30 published 
studies. These seven reasons were: prescription-medication affordability, lack of per-
ceived need for the medication, perceived medication concerns, lack of perceived drug 
efficacy, forgetfulness, access barriers, and patient knowledge. Researchers should 
standardize the content of PNA reasons to facilitate comparisons across patient sam-
ples. Many of the reasons for PNA can be addressed with patient-centered counselling 
at the time of prescribing. If we are to reduce PNA, doctor-patient communication 
must be improved to address patients beliefs about the need for the medication and 
their concerns about it.
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objeCtives: Adherence measurements developed for mono-pharmacotherapy, 
such as the Medication Possession Ratio (MPR), are not appropriate to calculate 
adherence to poly-pharmacotherapy. These standard metrics tend to over/under 
estimate adherence in patients with treatment regimens consist of multiple medi-
cations. This study aimed to develop a new method for calculating medication 
adherence in patients using poly-pharmacotherapy by linking prescribing and 
administration data of general practitioners (GPs), and pharmacy dispensing 
records. Methods: We evaluated existing methods for calculating medication 
adherence from dispensing data records. Standards for estimating medication 
adherence to poly-pharmacotherapy were defined. A new approach to calculate 
adherence to poly-pharmacotherapy was developed. Results: The proposed 
new approach for estimating medication adherence to poly-pharmacotherapy 
consists 2 novel indexes (the multiple-Medications Prescribing Ratio [mMPrR] and 
the multiple-Medications Possession Ratio [mMPR]) and a medication adherence 
visualization tool (the Prescription and Medication Possession Graph [PMPG]). The 
mMPrP is for calculating adherence to prescribe medications and the mMPR to (re)fill 
prescriptions. The PMPG completes the mMPrR and the mMPR with indicating medi-
cation adherence in time and allowing to evaluate tendencies in the observation 
period. Among other parameters, number of medications, therapeutic indication, 
treatment length (e.g., chronic conditions requiring periodic treatment), dosage, 
generic and therapeutic switching, therapeutic duplication, and oversupply were 
considered for the construction of mMPrP, mMPR and PMPG. The face-validity of 
the approach were demonstrated with four illustrative cases (i.e., generic switch-
ing, therapeutic duplication, oversupply, periodic treatment). ConClusions: The 
proposed new method enables a more accurate measurement of adherence to poly-
pharmacotherapy compared to MPR. The mMPrP, the mMPR and the PMPG would 
allow GPs to identify substantial adherence issues during consultations and could 
be routinely used to enhance medication adherence in countries where GPs have 
access to pharmacy dispensing records of their patients such as in Hungary.
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objeCtives: Self-care with non-steroidal anti-inflammatory drugs (NSAIDs), etc. 
is widely used for pelvic pain relief in dysmenorrhea patients in Japan; however, 
guideline-recommended medical intervention consists of low-dose estrogen and 
progestin hormonal combinations (LEP). This study aims to assess the cost-effec-
tiveness of intervention including LEP for the prevention of endometriosis and/or 
disease progression of dysmenorrhea, compared to self-care, in Japan. Methods: 
A Markov model with a 43-year time horizon and annual cycles was constructed. 
The model consisted of five major health states with four sub-medical states based 
on gynecologists’ consensus. The analyses were conducted from social, payer’s and 
woman’s perspectives. Transition probabilities among health and medical states were 
derived from epidemiological patient surveys. Disease-associated direct costs, such as 
inpatient, outpatient, surgery, and prescription and over-the-counter (OTC) drug costs 
were included. Utility measures were collected prospectively from patients with stage 
I-IV endometriosis using a visual analogue scale. An annual discount rate at 3% was 
considered. Sensitivity analyses were performed to examine the impact of uncertain-
ties. Results: Base case outcomes indicated that intervention would be superior to 
self-care when only considering direct costs (cost-saving amount of approximately 
240,000 JPY, with 4.4 incremental quality-adjusted life-years [QALYs] gained). From 
the payer’s perspective, intervention would be more cost-effective than self-care, as 
the incremental cost-effectiveness ratio (ICER) yielded 350,000 JPY per QALY gained. 
A tornado diagram depicting the deterministic sensitivity analysis was constructed, 
and robustness of the base case was confirmed. A probabilistic analysis resulting from 
10,000-time Monte Carlo simulations demonstrated efficiency at Willingness-To-Pay 
thresholds of 5,000,000 JPY in more than 90% of the population. ConClusions: Our 
analysis demonstrated that, in Japan, intervention would be more cost-effective than 
self-care in preventing endometriosis and/or disease progression for patients with 
dysmenorrhea. These findings could be used to inform health-care decision-making 
in women with dysmenorrhea and health-policy makers.
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objeCtives: This study reviews adherence metrics for Phase IV studies. Methods: 
We conducted a review of adherence metrics in the public domain. We critically 
appraised these metrics for use in Phase IV studies. Results: We identified 70 
unique self-report measures of adherence. One quarter (26%) were generic and the 
remaining were disease specific. Instrument length ranged from one to 78 items. 
One third (34%) only measured adherence behaviors, 37% only measured beliefs and 
attitudes, and 29% measured both. Just over one quarter (29%) were developed using 
a conceptual framework. One-fifth (21%) involved qualitative patient input during 
item generation or pretesting. Just over one-half (57%) had evidence of internal-
consistency reliability, and far fewer had evidence of test-retest reliability (23%). 
One half (50%) had evidence of validity vis á vis other self-report measures, 23% vis 
á vis other adherence metrics, and 19% vis á vis clinical criteria. Few had evidence 
of predictive (24%) or postdictive (13%) validity. ConClusions: Few adherence 
measures have been developed with true patient-centerednesss. There has been no 
standardization of the content of adherence behaviors or beliefs. Instrument vali-
dation has been inconsistent in its breadth and depth. Because of the importance 
of medication adherence to payers, providers, pharmacies, and pharmaceutical 
companies, the time seems opportune to conceptualize, develop, and validate a 
generic adherence measure that can be used in Phase IV studies across different 
disease and patient groups. Standardization of content would allow for the assess-
ment of adherence behaviors and beliefs between and across existing and novel 
therapies. There should be a minimum set of adherence concepts that apply across 
therapeutic areas. The new measure should be developed with patient input (con-
cept elicitation) and verified as to its comprehension and relevance using cognitive 
debriefing. The scientific basis of medication adherence would be advanced through 
the development and validation of a standardized generic measure that assesses 
adherence behaviors and beliefs.
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objeCtives: A systematic review of scientific articles was accomplished in order to 
identify personal factors used as predictors of adherence to medication. Methods: 
PubMed, PsycINFO, and cross-references were consulted using standardized queries. 
Original works were summarized using a pre-stablished set of content indicators. A 
multi-criteria decision analysis tool was developed to assess research quality, using 
12 independent criteria: Explicative model, adherence measure, predictive validity, 
pathologies studied, concurrent validity, structural validity, construct validity, dis-
criminant validity, sample size, study type, theoretical framework, and bibliographic 
review. Each criteria was valued as very good (100), good (80), acceptable (60), and 
bad (0/20); and a weighted sum was obtained considering all criteria. Valuations 
were carried out by two independent researchers and lack of agreement was dis-
entangled by a third reviewer. Results: A total of 113,560 studies were identified 
related to “adherence” and “persistence” between 1980 (454 studies) and May 2015, 
exhibiting an exponential growth rate with a maximum of 8,744 studies in 2014. 
After refining our search for personal predictive factors we ended with 272 articles 
